Osmotic demyelination syndrome in cancer patients: Risk even without rapid sodium correction - a scoping review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Osmotic demyelination syndrome (ODS) is a serious complication in cancer patients, often presenting with varied symptoms and under-recognized. Careful sodium management and prompt diagnosis are vital for improving outcomes in malignancy-associated ODS.
Area Of Science
- Neurology
- Oncology
- Medical Research
Background
- Osmotic demyelination syndrome (ODS) is a neurological complication.
- Cancer patients are susceptible to ODS due to complex factors.
- ODS can manifest with diverse and often subtle clinical signs.
Purpose Of The Study
- To characterize the clinical features of ODS in cancer patients.
- To review therapeutic strategies for ODS in this population.
- To determine prognostic outcomes associated with ODS in cancer.
Main Methods
- A systematic literature review was conducted from January 1950 to March 2024.
- Databases searched included PubMed, Embase, Cochrane Library, and Web of Science.
- Studies focused on ODS in cancer patients, excluding non-malignant cases and benign lesions.
Main Results
- Twenty-two cases of cancer-associated ODS were identified.
- Presentations varied from asymptomatic to severe consciousness disorders.
- Most patients received symptomatic or cancer treatment; few received immunotherapy.
Conclusions
- ODS is an under-recognized complication in cancer patients.
- Variable clinical presentations can mimic other conditions.
- Cautious sodium management and timely intervention are critical for prognosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
